GlassScriptPhysician profile
William K Mcmillan
NPI 1831117415
$1,155.22
in general payments reported to CMS, 2019-2025
26 companies · $31.41 in 2025
The $31.41 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $81.99 · 2021: $147 · 2022: $234 · 2023: $201 · 2024: $92.58 · 2025: $31.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $324.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $280.26 | 2019-2024 | Prolia, Evenity, Otezla |
| Pfizer INC. | $75.41 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $74.27 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $69.62 | 2019 | |
| Abbvie INC. | $67.25 | 2022-2023 | |
| Dexcom, INC. | $61.39 | 2023-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $51.08 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.48 | 2019 | |
| Merck Sharp & Dohme LLC | $42.80 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.41 | 2022 | |
| Novo Nordisk INC | $40.02 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $36.46 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $34.49 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $34.12 | 2023 | Austedo, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $29.69 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $23.00 | 2019-2021 | |
| Abbott Laboratories | $21.94 | 2021 | |
| Mylan Specialty L.P. | $21.11 | 2020 | |
| Radius Health, INC. | $16.07 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.95 | 2023 | |
| Dermira, INC. | $14.99 | 2019 | |
| Lundbeck LLC | $14.02 | 2023 | Rexulti |
| Alkermes, INC. | $11.67 | 2020 | |
| Biogen, INC. | $11.35 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.13 | 2019 | |
| Organon LLC | $8.24 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mcmillan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.